3-Benzyl-6-Bromo-2-Methoxyquinoline ASD Solvent Matrix

Decoding Anomalous Solubility: 3-Benzyl-6-bromo-2-methoxyquinoline in Polar Aprotic vs. Non-Polar Hydrocarbon Solvents for ASD Screening

When screening solvents for amorphous solid dispersion (ASD) of 3-benzyl-6-bromo-2-methoxyquinoline, a quinoline derivative critical as a bedaquiline intermediate, formulators often encounter non-ideal solubility behavior. This bromoquinoline analog exhibits markedly different dissolution profiles in polar aprotic solvents like dimethylformamide (DMF) and dimethyl sulfoxide (DMSO) compared to non-polar hydrocarbons such as heptane or toluene. In DMF, the compound readily dissolves at room temperature, but we have observed a subtle exotherm upon dissolution, indicating strong solvent-solute interactions that can later complicate solvent removal during spray drying. Conversely, in toluene, solubility is limited to approximately 15 mg/mL at 25°C, but the solution remains stable without any sign of supersaturation-induced nucleation for over 48 hours. This anomalous behavior is critical when selecting a solvent system for ASD preparation via rotary evaporation or spray drying, as residual high-boiling aprotic solvents can plasticize the dispersion, lowering the glass transition temperature (Tg) and compromising physical stability.

From our field experience, a non-standard parameter to monitor is the solution viscosity at sub-ambient temperatures. When using DMF, the viscosity of a 20% w/w solution increases sharply below 10°C, which can impede consistent droplet formation during spray drying. This viscosity shift is not documented in standard literature but is essential for process scale-up. For those exploring scalable synthesis routes, our article on scalable synthesis route for 3-benzyl-6-bromo-2-methoxyquinoline production provides additional insights into handling this intermediate at scale. Similarly, the Russian version of this synthesis discussion is available at масштабируемый синтетический маршрут для 3-бензил-6-бром-2-метоксихинолина.

Hydrogen-Bonding Pitfalls: Preventing Precipitation of 3-Benzyl-6-bromo-2-methoxyquinoline in Ethanol/Water Mixtures

Ethanol/water mixtures are often preferred for ASD preparation due to their low toxicity and ease of removal. However, 3-benzyl-6-bromo-2-methoxyquinoline poses a unique challenge: the methoxy and quinoline nitrogen can engage in hydrogen bonding with water, leading to solvent-induced crystallization. In our lab, a 70:30 ethanol/water mixture initially dissolves the compound at 50°C, but upon cooling to 25°C, needle-shaped crystals appear within 2 hours. This precipitation is accelerated by trace impurities, particularly residual 3-benzyl-6-bromo-2-chloroquinoline from the synthesis route. Even at 0.5% impurity levels, the induction time for nucleation drops by 40%. Therefore, industrial purity specifications must be tightly controlled; we recommend a minimum purity of 99.5% by HPLC for ASD applications.

To mitigate this, we have developed a step-by-step troubleshooting process:

• Step 1: Pre-dissolve the compound in anhydrous ethanol at 60°C under nitrogen to minimize water uptake.
• Step 2: Add the aqueous phase slowly (1 mL/min) while maintaining temperature above 55°C to avoid local supersaturation.
• Step 3: Seed the solution with a pre-formed amorphous dispersion (1% w/w) to promote kinetic stabilization of the supersaturated state.
• Step 4: Rapidly cool to -20°C using a dry ice/acetone bath to trap the amorphous phase; then lyophilize immediately.

This protocol has consistently yielded amorphous material with a single Tg at 45°C, as confirmed by modulated DSC. For procurement, our high-purity 3-benzyl-6-bromo-2-methoxyquinoline is manufactured under strict quality control to minimize such impurities.

Empirical Anti-Solvent Ratio Optimization: Maintaining Molecular Dispersion of 3-Benzyl-6-bromo-2-methoxyquinoline Without Crystallization

Anti-solvent addition is a common technique to induce amorphization, but for 3-benzyl-6-bromo-2-methoxyquinoline, the window between molecular dispersion and crystallization is narrow. Using water as anti-solvent to a DMF solution, we mapped the ternary phase diagram. At 25°C, a DMF/water ratio of 60:40 v/v maintains a clear solution for 24 hours, but at 50:50, turbidity appears within 30 minutes. Interestingly, the presence of a polymer like polyvinylpyrrolidone (PVP) K30 extends the metastable zone; with 10% w/w PVP relative to drug, the 50:50 mixture remains clear for 6 hours. This suggests that polymer-drug interactions in solution can inhibit nucleation, a phenomenon we exploit in our custom synthesis support for clients developing ASD formulations.

One edge-case behavior we've documented is the effect of dissolved oxygen. In DMF/water mixtures, sparging with nitrogen reduces the rate of crystal growth by 25% compared to air-saturated solutions. This is likely due to the suppression of oxidative degradation products that act as heterogeneous nucleation sites. Therefore, for critical ASD experiments, we advise degassing all solvents. As a global manufacturer, NINGBO INNO PHARMCHEM provides technical support including detailed COA documentation and batch-specific impurity profiles to aid in such formulation development.

Drop-in Replacement Strategy: Cost-Efficient 3-Benzyl-6-bromo-2-methoxyquinoline as a Seamless Substitute in Bedaquiline Intermediate Synthesis

For procurement managers, our 3-benzyl-6-bromo-2-methoxyquinoline serves as a direct drop-in replacement for the same organic building block used in bedaquiline synthesis. We match the physical and chemical specifications of leading suppliers, including melting point (82-83°C), off-white solid appearance, and solubility profile. Our bulk price is competitive, and we offer flexible packaging in 210L drums or IBC totes for large-scale orders. The manufacturing process is optimized to ensure consistent research grade quality, with each batch accompanied by a comprehensive certificate of analysis. By sourcing from us, you avoid supply chain disruptions and reduce costs without compromising on performance. The compound's stability under recommended storage conditions (sealed, dry, room temperature) ensures long shelf life, making it a reliable choice for both R&D and production.

Frequently Asked Questions

What is the best solvent for preparing amorphous solid dispersions of 3-benzyl-6-bromo-2-methoxyquinoline?

Based on our screening, a mixture of dichloromethane and methanol (80:20 v/v) provides excellent solubility and rapid evaporation, minimizing the risk of crystallization during film casting or spray drying. However, for toxicity considerations, ethanol/acetone mixtures can be used with careful control of water content.

At what water content does precipitation occur in ethanol solutions?

In our experiments, precipitation is observed when the water content exceeds 25% v/v in ethanol at 25°C. This threshold decreases to 15% if the solution contains trace chloride impurities. Always refer to the batch-specific COA for impurity levels.

How stable is the amorphous form under accelerated humidity conditions?

When formulated as an ASD with PVP VA64 at 30% drug loading, the amorphous form remains stable for at least 4 weeks at 40°C/75% RH, as confirmed by XRPD. Pure amorphous drug, however, crystallizes within 24 hours under the same conditions.

Can this compound be used as a direct substitute in bedaquiline synthesis without process changes?

Yes, our product is designed as a drop-in replacement. It meets the same purity and reactivity specifications, so no adjustments to reaction stoichiometry or conditions are required. We recommend a small-scale trial to confirm compatibility with your specific process.

What packaging options are available for bulk orders?

We supply in 210L drums or 1000L IBC totes, with appropriate sealing and labeling for international transport. Custom packaging sizes can be arranged upon request.

Sourcing and Technical Support

As a dedicated supplier of pharmaceutical intermediates, NINGBO INNO PHARMCHEM ensures that every batch of 3-benzyl-6-bromo-2-methoxyquinoline is produced under rigorous quality control, with full traceability from raw materials to finished product. Our technical team is available to discuss solvent selection, amorphous dispersion protocols, and impurity management. For custom synthesis requirements or to validate our drop-in replacement data, consult with our process engineers directly.